Patents by Inventor Mitsuhiro Iwamoto
Mitsuhiro Iwamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958878Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).Type: GrantFiled: March 5, 2019Date of Patent: April 16, 2024Assignees: Daiichi Sankyo Company, Limited, Kobe Gakuin Educational FoundationInventors: Makoto Koizumi, Yoshiyuki Onishi, Takeshi Masuda, Mitsuhiro Iwamoto, Yukiko Sekiguchi, Kentaro Ito, Shinnosuke Tsuji, Masafumi Matsuo
-
Patent number: 11661021Abstract: A vehicle body front structure includes front frames, first and second bumper beams, sub-frames, gussets, and load transmission members. The front frames extend in a front-rear direction. The first bumper beam is disposed in front of the front frames. The first bumper beam extends in a vehicle width direction. The sub-frames are disposed below the front frames. The sub-frames extend in the front-rear direction. The second bumper beam is coupled to front ends of the sub-frames. Ends of the second bumper beam protrude further outward than the first bumper beam. Each gusset is coupled to a corresponding one of ends of the second bumper beam and a corresponding one of intermediate portions of the sub-frames. The gussets transmit an impact load to the intermediate portions. The load transmission members are coupled to the sub-frames. The load transmission members are disposed on outer side surfaces of the front frame.Type: GrantFiled: March 25, 2021Date of Patent: May 30, 2023Assignee: SUBARU CORPORATIONInventor: Mitsuhiro Iwamoto
-
Patent number: 11628223Abstract: A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].Type: GrantFiled: September 28, 2018Date of Patent: April 18, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro Toda, Yusuke Ota, Fuminao Doi, Masaki Meguro, Ichiro Hayakawa, Shinji Ashida, Takeshi Masuda, Takashi Nakada, Mitsuhiro Iwamoto, Naoya Harada, Tomoko Terauchi, Daisuke Okajima, Kensuke Nakamura, Hiroaki Uchida, Hirofumi Hamada
-
Publication number: 20230084707Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: April 5, 2022Publication date: March 16, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Patent number: 11583590Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: GrantFiled: December 6, 2021Date of Patent: February 21, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro Toda, Yusuke Ota, Fuminao Doi, Masaki Meguro, Ichiro Hayakawa, Shinji Ashida, Takeshi Masuda, Takashi Nakada, Mitsuhiro Iwamoto, Naoya Harada, Tomoko Terauchi, Daisuke Okajima, Kensuke Nakamura, Hiroaki Uchida, Hirofumi Hamada
-
Publication number: 20220395579Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: June 26, 2022Publication date: December 15, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Publication number: 20220378920Abstract: The present invention provides a conjugate of an oligonucleotide having a nucleic acid sequence expected to have a pharmacological effect in hepatic parenchymal cells with a biantennary GalNAc unit, or a pharmaceutically acceptable salt thereof, and a medicament or the like containing the same as an active component.Type: ApplicationFiled: September 9, 2020Publication date: December 1, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Mitsuhiro Iwamoto, Yukiko Sekiguchi, Kentaro Ito
-
Publication number: 20220125943Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: December 6, 2021Publication date: April 28, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Publication number: 20210331640Abstract: A vehicle body front structure includes front frames, first and second bumper beams, sub-frames, gussets, and load transmission members. The front frames extend in a front-rear direction. The first bumper beam is disposed in front of the front frames. The first bumper beam extends in a vehicle width direction. The sub-frames are disposed below the front frames. The sub-frames extend in the front-rear direction. The second bumper beam is coupled to front ends of the sub-frames. Ends of the second bumper beam protrude further outward than the first bumper beam. Each gusset is coupled to a corresponding one of ends of the second bumper beam and a corresponding one of intermediate portions of the sub-frames. The gussets transmit an impact load to the intermediate portions. The load transmission members are coupled to the sub-frames. The load transmission members are disposed on outer side surfaces of the front frame.Type: ApplicationFiled: March 25, 2021Publication date: October 28, 2021Inventor: Mitsuhiro IWAMOTO
-
Patent number: 11008392Abstract: The present invention provides a conjugate comprising a hANP peptide bonded via a polyethylene glycol linker to a glycan attached to Asn297 of a Fc-containing molecule (N297 glycan), or a pharmaceutically acceptable salt thereof, a medicament comprising the same as an active ingredient, a method for producing the same, etc.Type: GrantFiled: June 30, 2017Date of Patent: May 18, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Mitsuhiro Iwamoto, Shohei Oishi, Yukiko Sekiguchi, Hiroyuki Chaya, Ryuki Miyauchi, Takeshi Honda
-
Patent number: 11001819Abstract: The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.Type: GrantFiled: July 15, 2016Date of Patent: May 11, 2021Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshirou Kawaguchi, Kensuke Nakamura, Yukiko Sekiguchi, Mitsuhiro Iwamoto
-
Patent number: 10947289Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.Type: GrantFiled: July 22, 2015Date of Patent: March 16, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Mitsuhiro Iwamoto, Takahiro Yamaguchi, Yutaka Mori, Keiji Saito, Takeshi Honda, Takahiro Nagayama
-
Publication number: 20210040170Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.Type: ApplicationFiled: October 15, 2020Publication date: February 11, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Mitsuhiro IWAMOTO, Takahiro YAMAGUCHI, Yutaka MORI, Keiji SAITO, Takeshi HONDA, Takahiro NAGAYAMA
-
Publication number: 20200407394Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to the cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648G>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).Type: ApplicationFiled: March 5, 2019Publication date: December 31, 2020Applicants: DAIICHI SANKYO COMPANY, LIMITED, KOBE GAKUIN EDUCATIONAL FOUNDATIONInventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takeshi MASUDA, Mitsuhiro IWAMOTO, Yukiko SEKIGUCHI, Kentaro ITO, Shinnosuke TSUJI, Masafumi MATSUO
-
Publication number: 20200261594Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: September 28, 2018Publication date: August 20, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Publication number: 20190169293Abstract: The present invention provides a conjugate comprising a hANP peptide bonded via a polyethylene glycol linker to a glycan attached to Asn297 of a Fc-containing molecule (N297 glycan), or a pharmaceutically acceptable salt thereof, a medicament comprising the same as an active ingredient, a method for producing the same, etc.Type: ApplicationFiled: June 30, 2017Publication date: June 6, 2019Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Mitsuhiro IWAMOTO, Shohei OISHI, Yukiko SEKIGUCHI, Hiroyuki CHAYA, Ryuki MIYAUCHI, Takeshi HONDA
-
Publication number: 20180208915Abstract: The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.Type: ApplicationFiled: July 15, 2016Publication date: July 26, 2018Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshirou Kawaguchi, Kensuke Nakamura, Yukiko Sekiguchi, Mitsuhiro Iwamoto
-
Publication number: 20160017015Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.Type: ApplicationFiled: July 22, 2015Publication date: January 21, 2016Applicant: Daiichi Sankyo Company, LimitedInventors: Mitsuhiro IWAMOTO, Takahiro Yamaguchi, Yutaka Mori, Keiji Saito, Takeshi Honda, Takahiro Nagayama
-
Patent number: 9051255Abstract: To find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, the agent having excellent activity and high safety. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents an optionally substituted phenylene group; B represents an optionally substituted 4- to 10-membered heterocyclic group, an optionally substituted C6-C10 aryl group, or an optionally substituted C3-C10 cycloalkyl group; R1 represents a hydrogen atom or a C1-C3 alkyl group; R2 represents a hydrogen atom or a C1-C3 alkyl group; R3 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C3 alkoxy C1-C3 alkyl group, or a C1-C3 hydroxyalkyl group; R4 represents a hydrogen atom, a C1-C6 alkyl group, or a halogen atom; n represents an integer of 1 to 4; and X represents methylene, —O—, —NH—, —N(C1-C3 alkyl)-, —C(?O)—, —S—, —S(O)—, —S(O2)—, or a single bond.Type: GrantFiled: December 27, 2013Date of Patent: June 9, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Narihiro Toda, Rieko Takano, Takeshi Shida, Takahiro Katagiri, Mitsuhiro Iwamoto, Shinji Ashida, Mami Yamazaki
-
Publication number: 20140221391Abstract: To find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, the agent having excellent activity and high safety. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents an optionally substituted phenylene group; B represents an optionally substituted 4- to 10-membered heterocyclic group, an optionally substituted C6-C10 aryl group, or an optionally substituted C3-C10 cycloalkyl group; R1 represents a hydrogen atom or a C1-C3 alkyl group; R2 represents a hydrogen atom or a C1-C3 alkyl group; R3 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C3 alkoxy C1-C3 alkyl group, or a C1-C3 hydroxyalkyl group; R4 represents a hydrogen atom, a C1-C6 alkyl group, or a halogen atom; n represents an integer of 1 to 4; and X represents methylene, —O—, —NH—, —N(C1-C3 alkyl)-, —C(?O)—, —S—, —S(O)—, —S(O2)—, or a single bond.Type: ApplicationFiled: December 27, 2013Publication date: August 7, 2014Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro Toda, Rieko Takano, Takeshi Shida, Takahiro Katagiri, Mitsuhiro Iwamoto, Shinji Ashida, Mami Yamazaki